Virus News and Research

Latest Virus News and Research

Bristol-Myers Squibb signs definitive agreement to acquire Inhibitex

Bristol-Myers Squibb Company and Inhibitex, Inc. announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire Inhibitex for $26.00 per share in cash pursuant to a cash tender offer and second step merger.

8 Jan 2012

Anthrax defenses need to be strengthened say experts

It has been a decade since the anthrax attacks brought home the reality of bioterrorism and the nation has a stockpile of some basic tools to fight back against a few of the threats that worry defense experts the most.

8 Jan 2012

OCF to offer free oral cancer screenings in April 2012

Did you know that the fastest growing segment of the oral cancer community is young, healthy non-smokers? It's shocking but true. Exposure to the HPV-16 virus, the most common sexually transmitted infection, is now the leading cause of oral cancers in the U.S. There is little that can be done to stop this virus from spreading. Our only hope to save lives is through increased professional involvement and public awareness to generate early discovery of the disease process.

7 Jan 2012

Smokeless tobacco products in India associated with increased risk of oral cancer

The 2nd International Conference on the Frontiers in Prevention, Diagnosis & Therapy of Cancer was held on 7th Jan. 2012 at Allahabad, India and looked at the relationship of oral cancer with tobacco habits. Various innovations in oral cancer diagnosis, therapy and tobacco usage were discussed by experts from around the world.

7 Jan 2012

WHO confirms bird flu cases in Egypt, China

The WHO on Thursday "announced the deaths of two men from H5N1 avian influenza, one from Egypt and another from China whose death was reported earlier in the media," CIDRAP News reports. Both men are suspected to have contracted the virus from avian sources, although an investigation into the man from China's exposure to the virus is ongoing, according to news service.

7 Jan 2012

FDA approval of raltegravir offers new weapon to treat HIV infection in children

For children and adolescents with HIV infection, the recent Food and Drug Administration (FDA) approval of the use of raltegravir, an antiretroviral drug that slows the spread of HIV infection, offers a new weapon to treat HIV infection in children.

7 Jan 2012

Alnylam files CTA with the U.K. MHRA to initiate ALN-TTR02 Phase I trial in ATTR

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I clinical trial with ALN-TTR02, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis.

7 Jan 2012

New HIV vaccine candidates show promise in monkeys

"The quest for a vaccine against AIDS is gaining momentum, with research published Wednesday identifying promising new candidates that protected monkeys against a powerful strain of the virus and that soon could be tested in humans," the Wall Street Journal reports.

6 Jan 2012

Study shows how Epstein-Barr virus triggers MS

A new study from researchers at Queen Mary, University of London shows how a particular virus tricks the immune system into triggering inflammation and nerve cell damage in the brain, which is known to cause MS.

6 Jan 2012

Tetragenetics reports results from G-SOME H5N1 vaccine preclinical study

Tetragenetics Inc., a biotechnology company focused on the development of recombinant vaccines, today reported preclinical study results showing that an investigational nanoparticle-based influenza vaccine protects against a highly pathogenic H5N1 avian influenza strain.

6 Jan 2012

Hepatitis C vaccine succeeds in an early phase clinical trial

An early phase clinical trial of a hepatitis C vaccine has shown promising results, according to researchers at Oxford University. The virus causing Hepatitis C is a difficult one since it changes its appearance, making creation of a vaccine against it a challenge.

5 Jan 2012

Novel vaccine combinations can protect against infection by SIV

Results from a recent study show that novel vaccine combinations can provide partial protection against infection by Simian Immunodeficiency Virus (SIV) in rhesus monkeys.

5 Jan 2012

Investigational HSV vaccine shows promise against two genital herpes diseases

An investigational vaccine protected some women against infection from one of the two types of herpes simplex viruses that cause genital herpes, according to findings in the New England Journal of Medicine.

5 Jan 2012

Study reveals factors associated with prevention, control of HIV infection

New vaccine research in monkeys suggests that scientists are homing in on the critical ingredients of a protective HIV vaccine and identifies new HIV vaccine candidates to test in human clinical trials.

5 Jan 2012

Positive preliminary results from Alnylam's Phase I ALN-PCS trial on severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the achievement of positive preliminary results from its ongoing clinical trial of ALN-PCS, an RNAi therapeutic targeting PCSK9 for the treatment of severe hypercholesterolemia.

5 Jan 2012

Viewpoints: Sebelius on 'essential benefits'; WSJ columnist on Democrats' 'Mediscare' argument - is it a lie?

Insurance needs and health systems vary state to state, and experience tells us that the best way forward is not to mandate a one-size-fits-all answer. Instead, our approach gives states the flexibility to take their own paths, while ensuring they all end up in the best place possible: with an Affordable Insurance Exchange that offers access to comprehensive, quality, affordable health insurance to small business owners and individuals who currently have few good choices in an expensive and broken market.

5 Jan 2012

Scientists determine structure of endomannosidase enzyme

Scientists have determined the structure of the enzyme endomannosidase, significantly advancing our understanding of how a group of devastating human viruses including HIV and Hepatitis C hijack human enzymes to reproduce and cause disease.

4 Jan 2012

WHO issues warning about risks of research on human engineered bird flu

"The World Health Organization issued a stern warning on Friday to scientists who have engineered a highly pathogenic form of the deadly H5N1 bird flu virus, saying their work carries significant risks and must be tightly controlled," Reuters reports.

4 Jan 2012

Scientists discover chemical compound that inhibits poxviruses from replicating

A team of scientists from Boston University School of Medicine (BUSM) have identified a novel compound that inhibits viruses from replicating. The findings, which are published online in the Journal of Virology, could lead to the development of highly targeted compounds to block the replication of poxviruses, such as the emerging infectious disease Monkeypox.

4 Jan 2012

Bird flu updates

The latest bird flu virus that killed a 39-year-old bus driver in the southern Chinese city of Shenzhen over the weekend is not yet transmissible between humans, Chinese health authorities said. The man, who lived in Shenzhen just across the border from Hong Kong, died from multi-organ failure on Saturday, a week after being admitted to hospital with a fever brought on by the virus, state media reported.

3 Jan 2012